Geisinger will expand its precision medicine project beyond research to preventive care, the Danville, PA-based integrated health system announced Sunday. The project already reports clinically actionable genomic results to research participants and their primary care physicians, and plans to launch a clinical DNA pilot program with 1,000 patients in the next six months. “Understanding the genome warning signals of every patient will be an essential part of wellness planning and health management,” Geisinger President and CEO David Feinberg, M.D., told participants at the HLTH Conference in Las Vegas. “Geisinger patients will be able to work with their family physician to modify their lifestyle and minimize risks that may be revealed.”

Related News Articles

Chairperson's File
In today’s episode, I talk with Lynn Todman, vice president of health equity and community partnerships at Corewell Health. Our discussion focuses on the many…
Blog
As a pediatrician, I've seen the impact of pediatric sepsis firsthand — it's an aggressive and unrelenting adversary that knows neither geographic nor…
Headline
The House Energy and Commerce Health Subcommittee March 12 passed AHA-supported  legislation to reauthorize through 2029 the Dr. Lorna Breen Health Care…
Headline
Jonathan Ripp, M.D., chief wellness officer for the Icahn School of Medicine at Mount Sinai and one of the nation’s first, discusses his role and how the…
Headline
Suzanne Bentley, M.D., chief wellness officer at New York City Health and Hospitals Elmhurst, discusses the critical role of peer support in employee mental…
Blog
It’s common knowledge that the pandemic affected the mental well-being of health care workers, and we know that those effects linger. According to a 2022…